=> d ibib ab hitstr 1-8 117

L17 ANSWER 1 OF 8 USPATFULL

ACCESSION NUMBER: 2002:266303 USPATFULL
TITLE: 13-substituted methacycline compounds
INVENTOR(S): Nelson, Mark L., Wellesley, MA, UNITED STATES
Bhatia, Beena, Arlington, MA, UNITED STATES
McIntyre, Laura, Arlington, MA, UNITED STATES
Rennie, Glen, South Weymouth, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002147182	A1	20021010
APPLICATION INFO.:	US 2001-895796	A1	20010629 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-216580P	20000707 (60)
	US 1999-154701P	19990914 (60)
	US 2000-193972P	20000331 (60)
	US 2000-193879P	20000331 (60)
	US 2000-204158P	20000515 (60)
	US 2000-212030P	20000616 (60)
	US 2000-212471P	20000616 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Elizabeth A. Hanley, Esq., Lahive & Cockfield, LLP, 28 State Street, Boston, MA, 02109
NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1
LINE COUNT: 1104
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB 13-substituted methacycline compounds, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 13-substituted methacycline compounds are described.

IT **233586-00-0P**
(synthesis and antibacterial activity of tetracycline-type compds.)

RN 233586-00-0 USPATFULL
CN 2-Naphthacenecarboxamide, 9-(2-chloro-1,1-dimethylethyl)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-(1-oxopropoxy)-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 1 OF 8 USPATFULL (Continued)



RN 233586-24-8 USPATFULL
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-(1-oxopropoxy)-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233586-25-9 USPATFULL
CN 2-Naphthacenecarboxamide, 5-(benzoyloxy)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233586-26-0 USPATFULL
CN Benzeneacetic acid, (4S,4aR,5S,5aR,6R,12aS)-2-(aminocarbonyl)-4-

L17 ANSWER 1 OF 8 USPATFULL (Continued)

IT **233586-01-1P 233586-22-6P 233586-23-7P**
233586-24-8P 233586-25-9P 233586-26-0P
233586-27-1P 233586-28-2P 233586-29-3P
233586-30-6P 233586-31-7P
(synthesis and antibacterial activity of tetracycline-type compds.)

RN 233586-01-1 USPATFULL
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-9-[1,1-dimethyl-2-(1-piperidinyl)ethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-(1-oxopropoxy)-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233586-22-6 USPATFULL
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-5-(formyloxy)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233586-23-7 USPATFULL
CN 2-Naphthacenecarboxamide, 5-(acetyloxy)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

L17 ANSWER 1 OF 8 USPATFULL (Continued)
(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-naphthacenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233586-27-1 USPATFULL
CN Carbamic acid, dimethyl-, (4S,4aR,5S,5aR,6R,12aS)-2-(aminocarbonyl)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-naphthacenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233586-28-2 USPATFULL
CN Cyclopentanecarboxylic acid, (4S,4aR,5S,5aR,6R,12aS)-2-(aminocarbonyl)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-naphthacenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L17 ANSWER 1 OF 8 USPATFULL (Continued)



RN 233586-29-3 USPATFULL
CN Cyclobutanecarboxylic acid, (4S,4aR,5S,5aR,6R,12aS)-2-(aminocarbonyl)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-naphthacenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233586-30-6 USPATFULL
CN Cyclohexanecarboxylic acid, (4S,4aR,5S,5aR,6R,12aS)-2-(aminocarbonyl)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-naphthacenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L17 ANSWER 1 OF 8 USPATFULL (Continued)



RN 233586-31-7 USPATFULL
CN Cycloheptanecarboxylic acid, (4S,4aR,5S,5aR,6R,12aS)-2-(aminocarbonyl)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-naphthacenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 2 OF 8 USPATFULL
ACCESSION NUMBER: 2002:243607 USPATFULL
TITLE: 7-phenyl-substituted tetracycline compounds
INVENTOR(S): Nelson, Mark L., Wellesley, MA, UNITED STATES
Rennie, Glen, South Weymouth, MA, UNITED STATES
Koza, Darrell, Westerly, RI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002132798	A1	20020919
APPLICATION INFO.:	US 2001-882505	A1	20010615 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2000-US116632	20000616
	US 2000-212470P	20000616 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109
NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1
LINE COUNT: 1041
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB 7-phenyl-substituted tetracycline compounds, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7-phenyl-substituted tetracycline compounds are described.
IT **233586-00-0P**
(synthesis and antibacterial activity of tetracycline-type compds.)
RN 233586-00-0 USPATFULL
CN 2-Naphthacenecarboxamide, 9-(2-chloro-1,1-dimethylethyl)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-(1-oxopropoxy)-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **233586-01-1P 233586-22-6P 233586-23-7P**
233586-24-8P 233586-25-9P 233586-26-0P
233586-27-1P 233586-28-2P 233586-29-3P
233586-30-6P 233586-31-7P
(synthesis and antibacterial activity of tetracycline-type compds.)
RN 233586-01-1 USPATFULL
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-9-[1,1-dimethyl-2-(1-piperidinyl)ethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-(1-oxopropoxy)-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)

L17 ANSWER 2 OF 8 USPATFULL (Continued)

Absolute stereochemistry.



RN 233586-22-6 USPATFULL
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-5-(formyloxy)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233586-23-7 USPATFULL
CN 2-Naphthacenecarboxamide, 5-(acetyloxy)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233586-24-8 USPATFULL
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-9-[2-(dimethylamino)-1,1-

L17 ANSWER 2 OF 8 USPATFULL (Continued)
dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-(1-oxopropoxy)-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233586-25-9 USPATFULL
CN 2-Naphthacenecarboxamide, 5-(benzoyloxy)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233586-26-0 USPATFULL
CN Benzeneacetic acid, (4S,4aR,5S,5aR,6R,12aS)-2-(aminocarbonyl)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-naphthacenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L17 ANSWER 2 OF 8 USPATFULL (Continued)



RN 233586-27-1 USPATFULL
CN Carbamic acid, dimethyl-, (4S,4aR,5S,5aR,6R,12aS)-2-(aminocarbonyl)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-naphthacenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233586-28-2 USPATFULL
CN Cyclopentanecarboxylic acid, (4S,4aR,5S,5aR,6R,12aS)-2-(aminocarbonyl)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-naphthacenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L17 ANSWER 2 OF 8 USPATFULL (Continued)



RN 233586-29-3 USPATFULL
CN Cyclobutanecarboxylic acid, (4S,4aR,5S,5aR,6R,12aS)-2-(aminocarbonyl)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-naphthacenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233586-30-6 USPATFULL
CN Cyclohexanecarboxylic acid, (4S,4aR,5S,5aR,6R,12aS)-2-(aminocarbonyl)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-naphthacenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L17 ANSWER 2 OF 8 USPATFULL (Continued)



RN 233586-31-7 USPATFULL
CN Cycloheptanecarboxylic acid, (4S,4aR,5S,5aR,6R,12aS)-2-(aminocarbonyl)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-naphthacenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 3 OF 8 USPATFULL

ACCESSION NUMBER: 2002:236040 USPATFULL
TITLE: 7-phenyl-substituted tetracycline compounds
INVENTOR(S): Nelson, Mark L., Wellesley, MA, UNITED STATES
Ismail, Mohamed Y., Bedford, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002128238	A1	20020912
APPLICATION INFO.:	US 2001-883137	A1	20010615 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-212030P	20000616 (60)
	US 2000-212471P	20000616 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109
NUMBER OF CLAIMS: 64
EXEMPLARY CLAIM: 1
LINE COUNT: 1323
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB 7-phenyl-substituted tetracycline compounds which are substantially free of positional isomers, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7-phenyl-substituted tetracycline compounds are described. 7-substituted tetracycline compounds which are substantially free of positional isomers, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7-substituted tetracycline compounds are described.

IT **233586-00-0P**
(synthesis and antibacterial activity of tetracycline-type compds.)

RN 233586-00-0 USPATFULL
CN 2-Naphthacenecarboxamide, 9-(2-chloro-1,1-dimethylethyl)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-(1-oxopropoxy)-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **233586-01-1P 233586-22-6P 233586-23-7P**
233586-24-8P 233586-25-9P 233586-26-0P
233586-27-1P 233586-28-2P 233586-29-3P

L17 ANSWER 3 OF 8 USPATFULL (Continued)



RN 233586-24-8 USPATFULL
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-(1-oxopropoxy)-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233586-25-9 USPATFULL
CN 2-Naphthacenecarboxamide, 5-(benzoyloxy)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233586-26-0 USPATFULL
CN Benzeneacetic acid, (4S,4aR,5S,5aR,6R,12aS)-2-(aminocarbonyl)-4-

L17 ANSWER 3 OF 8 USPATFULL (Continued)
233586-30-6P 233586-31-7P
(synthesis and antibacterial activity of tetracycline-type compds.)

RN 233586-01-1 USPATFULL
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-9-[1,1-dimethyl-2-(1-piperidinyl)ethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-(1-oxopropoxy)-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233586-22-6 USPATFULL
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-5-(formyloxy)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233586-23-7 USPATFULL
CN 2-Naphthacenecarboxamide, 5-(acetyloxy)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

L17 ANSWER 3 OF 8 USPATFULL (Continued)
(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-naphthacenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233586-27-1 USPATFULL
CN Carbamic acid, dimethyl-, (4S,4aR,5S,5aR,6R,12aS)-2-(aminocarbonyl)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-naphthacenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233586-28-2 USPATFULL
CN Cyclopentanecarboxylic acid, (4S,4aR,5S,5aR,6R,12aS)-2-(aminocarbonyl)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-naphthacenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L17 ANSWER 3 OF 8 USPATFULL (Continued)



RN 233586-29-3 USPATFULL
CN Cyclobutanecarboxylic acid, (4S,4aR,5S,5aR,6R,12aS)-2-(aminocarbonyl)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-naphthacenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233586-30-6 USPATFULL
CN Cyclohexanecarboxylic acid, (4S,4aR,5S,5aR,6R,12aS)-2-(aminocarbonyl)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-naphthacenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L17 ANSWER 3 OF 8 USPATFULL (Continued)



RN 233586-31-7 USPATFULL
CN Cycloheptanecarboxylic acid, (4S,4aR,5S,5aR,6R,12aS)-2-(aminocarbonyl)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-naphthacenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 4 OF 8 USPATFULL

ACCESSION NUMBER: 2002:236039 USPATFULL
TITLE: 7-N-substituted phenyl tetracycline compounds
INVENTOR(S): Nelson, Mark L., Wellesley, MA, UNITED STATES
Koza, Darrell, Westerly, RI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002128237	A1	20020912
APPLICATION INFO.:	US 2001-882273	A1	20010615 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2000-US16672	20000616
	US 2000-212139P	20000616 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109
NUMBER OF CLAIMS: 48
EXEMPLARY CLAIM: 1
LINE COUNT: 1098
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB 7-substituted tetracycline compounds, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7-substituted tetracycline compounds are described.

IT **233586-00-0P**
(synthesis and antibacterial activity of tetracycline-type compds.)

RN 233586-00-0 USPATFULL
CN 2-Naphthacenecarboxamide, 9-(2-chloro-1,1-dimethylethyl)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-(1-oxopropoxy)-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **233586-01-1P 233586-22-6P 233586-23-7P**
233586-24-8P 233586-25-9P 233586-26-0P
233586-27-1P 233586-28-2P 233586-29-3P
233586-30-6P 233586-31-7P
(synthesis and antibacterial activity of tetracycline-type compds.)

RN 233586-01-1 USPATFULL
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-9-[1,1-dimethyl-2-(1-piperidinyl)ethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-(1-oxopropoxy)-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L17 ANSWER 4 OF 8 USPATFULL (Continued)



RN 233586-22-6 USPATFULL
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-5-(formyloxy)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233586-23-7 USPATFULL
CN 2-Naphthacenecarboxamide, 5-(acetyloxy)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233586-24-8 USPATFULL
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-(1-oxopropoxy)-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA

L17 ANSWER 4 OF 8 USPATFULL (Continued)
INDEX NAME)

Absolute stereochemistry.



RN 233586-25-9 USPATFULL
CN 2-Naphthacenecarboxamide, 5-(benzoyloxy)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233586-26-0 USPATFULL
CN Benzeneacetic acid, (4S,4aR,5S,5aR,6R,12aS)-2-(aminocarbonyl)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-naphthacenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L17 ANSWER 4 OF 8 USPATFULL (Continued)



RN 233586-29-3 USPATFULL
CN Cyclobutanecarboxylic acid, (4S,4aR,5S,5aR,6R,12aS)-2-(aminocarbonyl)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-naphthacenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233586-30-6 USPATFULL
CN Cyclohexanecarboxylic acid, (4S,4aR,5S,5aR,6R,12aS)-2-(aminocarbonyl)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-naphthacenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L17 ANSWER 4 OF 8 USPATFULL (Continued)



RN 233586-27-1 USPATFULL
CN Carbamic acid, dimethyl-, (4S,4aR,5S,5aR,6R,12aS)-2-(aminocarbonyl)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-naphthacenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233586-28-2 USPATFULL
CN Cyclopentanecarboxylic acid, (4S,4aR,5S,5aR,6R,12aS)-2-(aminocarbonyl)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-naphthacenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L17 ANSWER 4 OF 8 USPATFULL (Continued)



RN 233586-31-7 USPATFULL
CN Cycloheptanecarboxylic acid, (4S,4aR,5S,5aR,6R,12aS)-2-(aminocarbonyl)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-naphthacenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 5 OF 8 USPATFULL
ACCESSION NUMBER: 2002:228474 USPATFULL
TITLE: PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE THEREOF
INVENTOR(S): LEVY, STUART B., BOSTON, MA, UNITED STATES
NELSON, MARK L., WELLESLEY, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002123637	A1	20020905
APPLICATION INFO.:	US 1999-234847	A1	19990122 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-72262P	19980123 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
LINE COUNT: 1568
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention includes new substituted tetracycline-type compounds that exhibit significant antibacterial activity, including against both gram-positive and gram-negative bacteria. It has been found that compounds of the invention are highly active against both gram positive and gram negative tetracycline sensitive and tetracycline resistant bacteria.

IT **233586-00-0P**
(synthesis and antibacterial activity of tetracycline-type compds.)

RN 233586-00-0 USPATFULL
CN 2-Naphthacenecarboxamide, 9-(2-chloro-1,1-dimethylethyl)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-(1-oxopropoxy)-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **233586-01-1P 233586-22-6P 233586-23-7P**
233586-24-8P 233586-25-9P 233586-26-0P
233586-27-1P 233586-28-2P 233586-29-3P
233586-30-6P 233586-31-7P
(synthesis and antibacterial activity of tetracycline-type compds.)

L17 ANSWER 5 OF 8 USPATFULL (Continued)



RN 233586-24-8 USPATFULL
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-(1-oxopropoxy)-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233586-25-9 USPATFULL
CN 2-Naphthacenecarboxamide, 5-(benzoyloxy)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233586-26-0 USPATFULL
CN Benzeneacetic acid, (4S,4aR,5S,5aR,6R,12aS)-2-(aminocarbonyl)-4-

L17 ANSWER 5 OF 8 USPATFULL (Continued)
RN 233586-01-1 USPATFULL
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-9-[1,1-dimethyl-2-(1-piperidinyl)ethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-(1-oxopropoxy)-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233586-22-6 USPATFULL
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-5-(formyloxy)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233586-23-7 USPATFULL
CN 2-Naphthacenecarboxamide, 5-(acetyloxy)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

L17 ANSWER 5 OF 8 USPATFULL (Continued)
(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-naphthacenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233586-27-1 USPATFULL
CN Carbamic acid, dimethyl-, (4S,4aR,5S,5aR,6R,12aS)-2-(aminocarbonyl)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-naphthacenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233586-28-2 USPATFULL
CN Cyclopentanecarboxylic acid, (4S,4aR,5S,5aR,6R,12aS)-2-(aminocarbonyl)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-naphthacenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L17 ANSWER 5 OF 8 USPATFULL (Continued)



RN 233586-29-3 USPATFULL
CN Cyclobutanecarboxylic acid, (4S,4aR,5S,5aR,6R,12aS)-2-(aminocarbonyl)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-naphthacenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233586-30-6 USPATFULL
CN Cyclohexanecarboxylic acid, (4S,4aR,5S,5aR,6R,12aS)-2-(aminocarbonyl)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-naphthacenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L17 ANSWER 6 OF 8 USPATFULL
ACCESSION NUMBER: 2002:214256 USPATFULL
TITLE: Tetracycline compounds for treatment of Cryptosporidium parvum related disorders
INVENTOR(S): Levy, Stuart B., Boston, MA, UNITED STATES
Nelson, Mark L., Wellesley, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002115644	A1	20020822
APPLICATION INFO.:	US 2001-768189	A1	20010123 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-178519P	20000124 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109
NUMBER OF CLAIMS: 77
EXEMPLARY CLAIM: 1
LINE COUNT: 999
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods and compositions for treating Cryptosporidium parvum related disorders in a mammal are discussed. Several novel tetracycline compounds useful for treating Cryptosporidium parvum related disorders are also included.
IT **233586-00-0P**
(synthesis and antibacterial activity of tetracycline-type compds.)
RN 233586-00-0 USPATFULL
CN 2-Naphthacenecarboxamide, 9-(2-chloro-1,1-dimethylethyl)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-(1-oxopropoxy)-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **233586-01-1P 233586-22-6P 233586-23-7P**
233586-24-8P 233586-25-9P 233586-26-0P
233586-27-1P 233586-28-2P 233586-29-3P
233586-30-6P 233586-31-7P
(synthesis and antibacterial activity of tetracycline-type compds.)
RN 233586-01-1 USPATFULL
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-9-[1,1-dimethyl-2-(1-piperidinyl)ethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-(1-oxopropoxy)-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)

L17 ANSWER 5 OF 8 USPATFULL (Continued)



RN 233586-31-7 USPATFULL
CN Cycloheptanecarboxylic acid, (4S,4aR,5S,5aR,6R,12aS)-2-(aminocarbonyl)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-naphthacenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 6 OF 8 USPATFULL (Continued)
Absolute stereochemistry.



RN 233586-22-6 USPATFULL
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-5-(formyloxy)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233586-23-7 USPATFULL
CN 2-Naphthacenecarboxamide, 5-(acetyloxy)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233586-24-8 USPATFULL
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-

L17 ANSWER 6 OF 8 USPATFULL (Continued)
methyl-1,11-dioxo-5-(1-oxopropoxy)-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233586-25-9 USPATFULL
CN 2-Naphthacenecarboxamide, 5-(benzoyloxy)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233586-26-0 USPATFULL
CN Benzeneacetic acid, (4S,4aR,5S,5aR,6R,12aS)-2-(aminocarbonyl)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-naphthacenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L17 ANSWER 6 OF 8 USPATFULL (Continued)



RN 233586-27-1 USPATFULL
CN Carbamic acid, dimethyl-, (4S,4aR,5S,5aR,6R,12aS)-2-(aminocarbonyl)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-naphthacenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233586-28-2 USPATFULL
CN Cyclopentanecarboxylic acid, (4S,4aR,5S,5aR,6R,12aS)-2-(aminocarbonyl)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-naphthacenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L17 ANSWER 6 OF 8 USPATFULL (Continued)



RN 233586-29-3 USPATFULL
CN Cyclobutanecarboxylic acid, (4S,4aR,5S,5aR,6R,12aS)-2-(aminocarbonyl)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-naphthacenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233586-30-6 USPATFULL
CN Cyclohexanecarboxylic acid, (4S,4aR,5S,5aR,6R,12aS)-2-(aminocarbonyl)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-naphthacenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L17 ANSWER 6 OF 8 USPATFULL (Continued)



RN 233586-31-7 USPATFULL
CN Cycloheptanecarboxylic acid, (4S,4aR,5S,5aR,6R,12aS)-2-(aminocarbonyl)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-naphthacenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 7 OF 8 USPATFULL
ACCESSION NUMBER: 2002:192100 USPATFULL
TITLE: 7-and 9- carbamate, urea, thiourea, thiocarbamate, and heteroaryl-amino substituted tetracycline compounds
INVENTOR(S): Nelson, Mark L., Wellesley, MA, UNITED STATES
Levy, Stuart B., Boston, MA, UNITED STATES
Frechette, Roger, Reading, MA, UNITED STATES
Bowser, Todd E., Charlton, MA, UNITED STATES
Ismail, Mohamed Y., Bedford, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002103171	A1	20020801
APPLICATION INFO.:	US 2001-823884	A1	20010330 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-193972P	20000331 (60)
	US 2000-193879P	20000331 (60)
	US 2001-280367P	20010329 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109
NUMBER OF CLAIMS: 102
EXEMPLARY CLAIM: 1
LINE COUNT: 2421
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Substituted tetracycline compounds, methods of synthesis, and methods of use are discussed. Tetracyclines useful for treating tetracycline related disorders are also discussed. Intermediates useful for synthesizing other tetracycline compounds are also included.

IT **233586-00-0P**
(synthesis and antibacterial activity of tetracycline-type compds.)

RN 233586-00-0 USPATFULL
CN 2-Naphthacenecarboxamide, 9-(2-chloro-1,1-dimethylethyl)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-(1-oxopropoxy)-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **233586-01-1P 233586-22-6P 233586-23-7P 233586-24-8P 233586-25-9P 233586-26-0P**

L17 ANSWER 7 OF 8 USPATFULL (Continued)



RN 233586-24-8 USPATFULL
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-(1-oxopropoxy)-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233586-25-9 USPATFULL
CN 2-Naphthacenecarboxamide, 5-(benzoyloxy)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233586-26-0 USPATFULL
CN Benzeneacetic acid, (4S,4aR,5S,5aR,6R,12aS)-2-(aminocarbonyl)-4-

L17 ANSWER 7 OF 8 USPATFULL (Continued)
233586-27-1P 233586-28-2P 233586-29-3P 233586-30-6P 233586-31-7P
(synthesis and antibacterial activity of tetracycline-type compds.)

RN 233586-01-1 USPATFULL
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-9-[1,1-dimethyl-2-(1-piperidinyl)ethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-(1-oxopropoxy)-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233586-22-6 USPATFULL
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-5-(formyloxy)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233586-23-7 USPATFULL
CN 2-Naphthacenecarboxamide, 5-(acetyloxy)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

L17 ANSWER 7 OF 8 USPATFULL (Continued)
(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-naphthacenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233586-27-1 USPATFULL
CN Carbamic acid, dimethyl-, (4S,4aR,5S,5aR,6R,12aS)-2-(aminocarbonyl)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-naphthacenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233586-28-2 USPATFULL
CN Cyclopentanecarboxylic acid, (4S,4aR,5S,5aR,6R,12aS)-2-(aminocarbonyl)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-naphthacenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L17 ANSWER 7 OF 8 USPATFULL (Continued)



RN 233586-29-3 USPATFULL
CN Cyclobutanecarboxylic acid, (4S,4aR,5S,5aR,6R,12aS)-2-(aminocarbonyl)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-naphthacenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233586-30-6 USPATFULL
CN Cyclohexanecarboxylic acid, (4S,4aR,5S,5aR,6R,12aS)-2-(aminocarbonyl)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-naphthacenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L17 ANSWER 8 OF 8 USPATFULL

ACCESSION NUMBER: 2002:85560 USPATFULL
TITLE: 7-substituted fused ring tetracycline compounds
INVENTOR(S): Nelson, Mark L., Wellesley, MA, UNITED STATES
McIntyre, Laura, Cambridge, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002045602	A1	20020418
APPLICATION INFO.:	US 2001-852908	A1	20010510 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-204158P	20000515 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
LINE COUNT: 959
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB 7-substituted fused ring tetracycline compounds, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7-substituted fused ring tetracycline compounds are described.

IT **233586-00-0P**
(synthesis and antibacterial activity of tetracycline-type compds.)

RN 233586-00-0 USPATFULL
CN 2-Naphthacenecarboxamide, 9-(2-chloro-1,1-dimethylethyl)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-(1-oxopropoxy)-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **233586-01-1P 233586-22-6P 233586-23-7P**
233586-24-8P 233586-25-9P 233586-26-0P
233586-27-1P 233586-28-2P 233586-29-3P
233586-30-6P 233586-31-7P
(synthesis and antibacterial activity of tetracycline-type compds.)

RN 233586-01-1 USPATFULL
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-9-[1,1-dimethyl-2-(1-piperidinyl)ethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-(1-oxopropoxy)-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L17 ANSWER 7 OF 8 USPATFULL (Continued)



RN 233586-31-7 USPATFULL
CN Cycloheptanecarboxylic acid, (4S,4aR,5S,5aR,6R,12aS)-2-(aminocarbonyl)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-naphthacenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 8 OF 8 USPATFULL (Continued)



RN 233586-22-6 USPATFULL
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-5-(formyloxy)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233586-23-7 USPATFULL
CN 2-Naphthacenecarboxamide, 5-(acetyloxy)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233586-24-8 USPATFULL
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-(1-oxopropoxy)-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA

L17 ANSWER 8 OF 8 USPATFULL (Continued)
INDEX NAME)

Absolute stereochemistry.



RN 233586-25-9 USPATFULL
CN 2-Naphthacenecarboxamide, 5-(benzoyloxy)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233586-26-0 USPATFULL
CN Benzeneacetic acid, (4S,4aR,5S,5aR,6R,12aS)-2-(aminocarbonyl)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-naphthacenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L17 ANSWER 8 OF 8 USPATFULL (Continued)



RN 233586-29-3 USPATFULL
CN Cyclobutanecarboxylic acid, (4S,4aR,5S,5aR,6R,12aS)-2-(aminocarbonyl)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-naphthacenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233586-30-6 USPATFULL
CN Cyclohexanecarboxylic acid, (4S,4aR,5S,5aR,6R,12aS)-2-(aminocarbonyl)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-naphthacenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L17 ANSWER 8 OF 8 USPATFULL (Continued)



RN 233586-27-1 USPATFULL
CN Carbamic acid, dimethyl-, (4S,4aR,5S,5aR,6R,12aS)-2-(aminocarbonyl)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-naphthacenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 233586-28-2 USPATFULL
CN Cyclopentanecarboxylic acid, (4S,4aR,5S,5aR,6R,12aS)-2-(aminocarbonyl)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-naphthacenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L17 ANSWER 8 OF 8 USPATFULL (Continued)



RN 233586-31-7 USPATFULL
CN Cycloheptanecarboxylic acid, (4S,4aR,5S,5aR,6R,12aS)-2-(aminocarbonyl)-4-(dimethylamino)-9-[2-(dimethylamino)-1,1-dimethylethyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-5-naphthacenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d ibib ab fqhit 1-3

L22 ANSWER 1 OF 3 MARPAT COPYRIGHT 2002 ACS
ACCESSION NUMBER: 137:232491 MARPAT
TITLE: Preparation of tetracycline derivatives and their use as antibiotic agents
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: Eur. Pat. Appl., 19 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1241160	A1	20020918	EP 2001-500065	20010313
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
WO 2002072545	A2	20020919	WO 2002-US7856	20020313
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: EP 2001-500065 20010313

AB Tetracycline derivs., such as I [R = H, halogen, alkyl, NRaRb; R1, Ra, Rb = H, alkyl; R2 = H, O-alkyl, OH; R3 = H, OH; R1R3 = CH2; R4 = H, alkyl; R5 = H, alkyl, alkoxycarbonyl; X = NRxRy, O-alkyl optionally substituted by OH, OMe, halogen, amino, CF3; Rx, Ry = H, benzyl, cycloalkyl, alkenyl, alkynyl, alkyl optionally substituted by one or more groups selected from OH, OMe, halogen, NRaRb, CF3, alkylcycloalkyl, alkylheterocycle, alkylamino, alkylthio or together Rx and Ry form a heterocycle], pharmaceutically acceptable derivs. and solvates thereof, were prepd. for the treatment of Gram-pos., Gram-neg. and community acquired infections. Growth-inhibitory activity of prepd. tetracycline derivs. I was detd. against Staphylococcus aureus, Enterococcus hirae, Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and Escherichia coli. Thus, tetracycline deriv. (II) exhibited MIC value = 16 .mu.g/mL against S. aureus RN4250.

MSTR 1



L22 ANSWER 1 OF 3 MARPAT COPYRIGHT 2002 ACS (Continued)
G2 = 40

G3 = alkoxy<(1-6)>
G4 = NH
MPL: claim 1
NTE: and pharmaceutically acceptable derivatives and solvates

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 2 OF 3 MARPAT COPYRIGHT 2002 ACS
ACCESSION NUMBER: 135:288637 MARPAT
TITLE: Preparation of 7-and 9-carbamate, urea, thiourea, thiocarbamate, and heteroaryl-amino substituted tetracycline derivatives for pharmaceutical use as antibiotics
INVENTOR(S): Nelson, Mark L.; Levy, Stuart B.; Prechette, Roger; Bowser, Todd E.; Ismail, Mohamed Y.
PATENT ASSIGNEE(S): Trustees of Tufts College, USA
SOURCE: PCT Int. Appl., 88 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001074761	A1	20011011	WO 2001-US10342	20010331
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002103171	A1	20020801	US 2001-823884	20010330
US 2002128237	A1	20020912	US 2001-882273	20010615
US 2002147182	A1	20021010	US 2001-895796	20010629

PRIORITY APPLN. INFO.:
US 2000-193879P 20000331
US 2000-193972P 20000331
US 2001-280367P 20010329
US 1999-154701P 19990914
US 2000-204158P 20000515
US 2000-212030P 20000616
US 2000-212139P 20000616
US 2000-212471P 20000616
WO 2000-US16672 20000616
US 2000-216580P 20000707

AB Tetracycline derivs., such as I [R5 = H, OH, acyloxy, etc.; R6 = H, Me, alkyl, etc.; R7, R9 = arylamino, urea, thiourea, carbamate, thiocarbamate, etc.; R8 = H, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, etc.], were prepd. for pharmaceutical use as antibiotics. Thus, doxycycline deriv. I (R5 = OH, R6 = Me, R7 = R8 = H, R9 = 1-naphthylaminocarbonylamino) was prepd. by nitration of doxycycline with potassium nitrate, Pd/C catalyzed hydrogenation of the nitrate to form 9-aminodoxycycline I (R5 = OH, R6 = Me, R7 = R8 = H, R9 = NH2) followed by formation of the desired urea by reaction of 9-aminodoxycycline with 1-naphthylisocyanate. The prepd. tetracycline derivs. were tested for efficacy against common bacterial strains, such as E. coli, S. aureus, E. hirae, and E. faecalis.

MSTR 1

L22 ANSWER 2 OF 3 MARPAT COPYRIGHT 2002 ACS (Continued)



G1 = 24



G2 = NH2
G6 = NMe2
G8 = OH
G10 = 142



G16 = NH
DER: and pharmaceutically acceptable salts
MPL: claim 1
NTE: substitution is restricted

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 3 OF 3 MARPAT COPYRIGHT 2002 ACS
ACCESSION NUMBER: 124:55682 MARPAT
TITLE: 9-(substituted amino)-6.alpha.-deoxy-5-oxytetracycline derivatives, their preparation and their use as antibiotics
INVENTOR(S): Su, Wei-guo
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9522529	A1	19950824	WO 1995-IB26	19950112
W: AU, BR, CA, CN, CZ, HU, JP, KR, MX, NO, NZ, PL, RU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9512790	A1	19950904	AU 1995-12790	19950112
EP 745065	A1	19961204	EP 1995-903899	19950112
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 09501952	T2	19970225	JP 1995-521686	19950112
JP 2784847	B2	19980806		
FI 9500700	A	19950818	FI 1995-700	19950216
BR 9500659	A	19951031	BR 1995-659	19950216
US 5834450	A	19981110	US 1996-682640	19960722
PRIORITY APPLN. INFO.:			US 1994-198801	19940217
			WO 1995-IB26	19950112

AB Title compds. I [R1 = H, aminoalkyl; R2 = H, acyl; R3 = acyl, alkanesulfonyl] and their pharmaceutically acceptable salts were prepd. I exhibit antibiotic activity against a wide range of gram-pos. and gram-neg. organisms, including organisms that are resistant to tetracycline antibiotics (no data). Thus, doxycycline was converted to the 9-nitro deriv., which was reduced to the amine and treated with Me2NCH2COCl.HCl to give 9-dimethylglycylaminodoxycycline dihydrochloride.

MSTR 1



G1 = NH2
G10 = 57

L22 ANSWER 3 OF 3 MARPAT COPYRIGHT 2002 ACS (Continued)

DER: or pharmaceutically acceptable salts
MPL: claim 1
STE: 240-D,L

```
=> d his

     (FILE 'HOME' ENTERED AT 12:02:01 ON 18 DEC 2002)

     FILE 'REGISTRY' ENTERED AT 12:02:06 ON 18 DEC 2002
L1              STRUCTURE UPLOADED
L2           13 S L1
L3          354 S L1 FULL
L4              STRUCTURE UPLOADED
L5           13 S L4 FULL SUB=L3

     FILE 'USPATFULL' ENTERED AT 12:04:26 ON 18 DEC 2002
L6            8 S L5

     FILE 'CAPLUS' ENTERED AT 12:06:25 ON 18 DEC 2002
L7            6 S L5
L8            0 S L7 NOT L6

     FILE 'MARPAT' ENTERED AT 12:07:33 ON 18 DEC 2002
L9           11 S L5 FULL
L10          10 S L9/COM

     FILE 'REGISTRY' ENTERED AT 12:09:52 ON 18 DEC 2002
L11             STRUCTURE UPLOADED
L12          13 S L11 FULL SUB=L3
L13           0 S L12 NOT L5
L14             STRUCTURE UPLOADED
L15          31 S L14 FULL SUB=L3
L16          18 S L15 NOT L12

     FILE 'USPATFULL' ENTERED AT 12:12:36 ON 18 DEC 2002
L17           8 S L16
L18           0 S L17 NOT PY>=1998

     FILE 'CAPLUS' ENTERED AT 12:12:59 ON 18 DEC 2002

     FILE 'USPATFULL' ENTERED AT 12:13:08 ON 18 DEC 2002

     FILE 'CAPLUS' ENTERED AT 12:15:09 ON 18 DEC 2002
L19           7 S L16
L20           0 S L19 NOT L17

     FILE 'MARPAT' ENTERED AT 12:15:31 ON 18 DEC 2002
L21          14 S L15 FULL
L22           3 S L21 NOT L9

=> file reg
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               64.78     489.17

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                               -1.77      -7.67

FILE 'REGISTRY' ENTERED AT 12:18:38 ON 18 DEC 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
```

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 17 DEC 2002 HIGHEST RN 476608-54-5
DICTIONARY FILE UPDATES: 17 DEC 2002 HIGHEST RN 476608-54-5

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> d l14
L14 HAS NO ANSWERS
L14 STR



Structure attributes must be viewed using STN Express query preparation.